IPXL - Impax Laboratories, Inc.

. Currency in USD
Stock chart is not supported by your current browser
Previous CloseN/A
OpenN/A
BidN/A x N/A
AskN/A x N/A
Day's RangeN/A - N/A
52 Week Rangeundefined - undefined
VolumeN/A
Avg. VolumeN/A
Market CapN/A
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • A Performance Overview of Merck’s Cardiovascular Segment
    Market Realist7 months ago

    A Performance Overview of Merck’s Cardiovascular Segment

    Merck & Co.’s (MRK) Zetia generated revenues of $165 million in the third quarter, reflecting a ~48% YoY (year-over-year) decline and a ~27% sequential decline. Zetia reported net revenues of $696 million in the first nine months of the year compared to $1 billion in the same period of 2017, reflecting a ~32% YoY decline.

  • How Is Merck’s Cardiovascular Portfolio Positioned after H1 2018?
    Market Realist10 months ago

    How Is Merck’s Cardiovascular Portfolio Positioned after H1 2018?

    In the second quarter of 2018, Merck’s (MRK) Zetia generated revenues of $226.0 million compared to $367.0 million in the second quarter of 2017, reflecting a ~38% year-over-year (or YoY) decline and a ~26% sequential decline. In the second quarter of 2018, in the US and international markets (outside the US markets), Zetia generated revenues of $8.0 million and $218.0 million, respectively, compared to $122.0 million and $246.0 million in the second quarter of 2017.

  • What Is Impax Asset Management Group plc’s (LON:IPX) Share Price Doing?
    Simply Wall St.last year

    What Is Impax Asset Management Group plc’s (LON:IPX) Share Price Doing?

    Impax Asset Management Group plc (LON:IPX), a capital markets company based in United Kingdom, led the AIM gainers with a relatively large price hike in the past couple of weeks.Read More...